

General Information

Name: Dr. rer. nat. Billy Jebaraj
Date of Birth: 02.11.1983
Gender: Male
Address: Division of CLL,
Department of Internal Medicine III, Ulm University
Albert-Einstein-Allee 23, 89081 Ulm, Germany
Phone: +49 731 500 45838
E-Mail: billy.jebaraj@uniklinik-ulm.de
Current Position: Post doctoral Researcher
Children: 2

Academic Education

2005-2007 Master of Science (M.Sc.), Madurai Kamaraj University, Madurai, India
2002-2005 Bachelor of Science (B.Sc.), Kamaraj College Thoothukudi, India

Academic Degrees

2013 Dr. rer. nat. (Ph.D), University of Ulm, Germany, Department of Internal Medicine III, Advisor: Prof. Stephan Stilgenbauer
2007 Master's (M.Sc.) thesis, Madurai Kamaraj University, India, Department of Microbial Technology, Advisor: Prof. S. Shanmugasundaram
2005 Bachelor's (B.Sc.) thesis, Kamaraj College, India, Department of Microbiology, Advisor: Dr. J. Jeyakumar

Professional Experience

Since 2013 Post-doctoral Fellow, Research Group of Prof. Dr. Stephan Stilgenbauer, Department of Internal Medicine III, Ulm University, Germany
2007-2008 Teaching assistant, Department of Microbial Technology, Madurai Kamaraj University, India

Miscellaneous

Awards and Honors:

2017 Abstract Achievement Award, American Society of Hematology Annual meeting, 2017
2013 Abstract Achievement Award, American Society of Hematology Annual meeting, 2013
2008-2011 PhD scholarship, International Graduates School in Molecular Medicine, University of Ulm, Germany
2005 University rank holder (20th) in B.Sc. Manonmaniam Sundaranar University, Tirunelveli, India

Publications

1. Qi J, Endres S, Yosifov DY, Tausch E, Dheenadayalan RP, Gao X, Müller A, Schneider C, Mertens D, Gierschik P, Wist M, [Jebaraj BMC](#), Stilgenbauer S. Acquired BTK mutations associated with resistance to non-covalent BTK inhibitors. **Blood Adv.** 2023 Jan 20. [Online ahead of print].
2. Tausch E, Ljungström V, Agathangelidis A, Zapatka M, Scarfò L, [Jebaraj BMC](#), Yosifov DY, Müller A, Munugalavadla V, Degenhardt JD, Ghia P, Rosenquist R, Stilgenbauer S. Secondary resistance to idelalisib is characterized by upregulation of *IGF1R* rather than MAPK/ERK pathway mutations. **Blood.** 2022 Jun 2;139(22):3340-3344

3. Bloehdorn J, Krzykalla J, Holzmann K, Gerhardinger A, Jebaraj BMC, Bahlo J, Humphrey K, Tausch E, Robrecht S, Mertens D, Schneider C, Fischer K, Hallek M, Döhner H, Benner A, Stilgenbauer S. Integrative prognostic models predict long-term survival after immunochemotherapy in chronic lymphocytic leukemia patients. **Haematologica**. 2022;107(3):615-624.
4. Jebaraj BMC, Müller A, Dheenadayalan RP, Endres S, Roessner PM, Seyfried F, Walliser C, Wist M, Qi J, Tausch E, Mertens D, Fox JA, Debatin KM, Meyer LH, Taverna P, Seiffert M, Gierschik P, Stilgenbauer S. Evaluation of vecabrutinib as a model for noncovalent BTK/ITK inhibition for treatment of chronic lymphocytic leukemia. **Blood**. 2022 Feb 10;139(6):859-875.
5. Bloehdorn J, Braun A, Taylor-Weiner A, Jebaraj BMC, Robrecht S, Krzykalla J, Pan H, Giza A, Akylzhanova G, Holzmann K, Scheffold A, Johnston HE, Yeh RF, Klymenko T, Tausch E, Eichhorst B, Bullinger L, Fischer K, Weisser M, Robak T, Schneider C, Gribben J, Dahal LN, Carter MJ, Elemento O, Landau DA, Neuberg DS, Cragg MS, Benner A, Hallek M, Wu CJ, Döhner H, Stilgenbauer S, Mertens D. Multi-platform profiling characterizes molecular subgroups and resistance networks in chronic lymphocytic leukemia. **Nat Commun**. 2021 Sep 13;12(1):5395.
6. Jebaraj BMC, Stilgenbauer S. Telomere Dysfunction in Chronic Lymphocytic Leukemia. **Front Oncol**. 2021 Jan 15;10:612665.
7. Jebaraj BMC, Tausch E, Landau DA, Bahlo J, Robrecht S, Taylor-Weiner AN, Bloehdorn J, Scheffold A, Mertens D, Böttcher S, Kneba M, Jäger U, Zenz T, Wenger MK, Fingerle-Rowson G, Wendtner C, Fink AM, Wu CJ, Eichhorst B, Fischer K, Hallek M, Döhner H, Stilgenbauer S. Short telomeres are associated with inferior outcome, genomic complexity, and clonal evolution in chronic lymphocytic leukemia. **Leukemia**. 2019 Sep;33(9):2183-2194.
8. Jebaraj BMC*, Scheffold A*, Tausch E, Bloehdorn J, Ghia P, Yahiaoui A, Dolnik A, Blätte TJ, Bullinger L, Dheenadayalan RP, Li L, Schneider C, Chen SS, Chiorazzi N, Dietrich S, Seiffert M, Tannheimer S, Döhner H, Mertens D, Stilgenbauer S. IGF1R as druggable target mediating PI3K- δ inhibitor resistance in a murine model of chronic lymphocytic leukemia. **Blood**. 2019;134(6):534-547. *Equal contribution.
9. Jebaraj BMC*, Steinbrecher D*, Schneider C, Edelmann J, Cymbalista F, Leblond V, Delmer A, Ibach S, Tausch E, Scheffold A, Bloehdorn J, Hallek M, Dreger P, Döhner H, Stilgenbauer S. Telomere length in poor-risk chronic lymphocytic leukemia: associations with disease characteristics and outcome. **Leuk Lymphoma**. 2018 Jul;59(7):1614-1623. *Equal contribution.
10. Jebaraj BMC*, Scheffold A*, Jaramillo S, Tausch E, Steinbrecher D, Hahn M, Böttcher S, Ritgen M, Bunjes D, Zeis M, Stadler M, Uharek L, Scheid C, Hegenbart U, Hallek M, Kneba M, Schmitz N, Döhner H, Dreger P, Stilgenbauer S. Impact of telomere length on the outcome of allogeneic stem cell transplantation for poor-risk chronic lymphocytic leukaemia: results from the GCLLSG CLL3X trial. **Br J Haematol**. 2017 Oct;179(2):342-346. *Equal contribution.